Color enhancement

Color enhancement can be described as the experience of colors becoming extremely bright or vivid and standing out.^[1]^[2] During this experience, reds may seem “redder”, greens may seem “greener, ” etc and all colors will likely have become much more distinct, powerful and intense to look at than they comparatively would be during everyday sober living.^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]

Studies have also suggested an accompanying effect of decreased hue discrimination resulting in anecdotal accounts of percieving colours which are seemingly impossible.^[3]^[4]

Colour enhancement is often accompanied by other coinciding effects such as acuity enhancement and pattern recognition enhancement.^[9]^[10] It is most commonly induced under the influence of mild dosages of psychedelic compounds, such as LSD, psilocybin, and mescaline. However, it can also occur to a lesser extent under the influence of certain stimulants and dissociatives such as MDMA or 3-MeO-PCP.

Image examples

Psychoactive substances

Compounds within our psychoactive substance index which may cause this effect include:

... further results

Experience reports

Annectdotal reports which describe this effect with our experience index include:

External links

Chromatic adaptation (Wikipedia)

References

↑ Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119
↑ Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006
↑ ^3.0 ^3.1 Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349
↑ ^4.0 ^4.1 Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560
↑ Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346
↑ Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf
↑ Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753. https://dx.doi.org/10.3389%2Ffpsyg.2013.00753
↑ Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26. https://doi.org/10.1016/S0376-8716(02)00243-0
↑ ^9.0 ^9.1 Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9
↑ ^10.0 ^10.1 Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749

[1] Abraham, H. D. (1983). Visual phenomenology of the LSD flashback. Arch Gen Psychiatry, 40(8), 886-887. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/493119

[2] Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug & Alcohol Dependence, 114(1), 63-64. https://doi.org/10.1016/j.drugalcdep.2010.09.006

[DecreasedHueDiscrimination-3] 3.0 ^3.1 Hartman, A. M., & Hollister, L. E. (1963). Effect of mescaline, lysergic acid diethylamide and psilocybin on color perception. Psychopharmacologia, 4(6), 449-451. https://doi.org/10.1007/BF00403349

[ImpossibleColours-4] 4.0 ^4.1 Kleinman, J. E., Gillin, J. C., & Wyatt, R. J. (1977). A comparison of the phenomenology of hallucinogens and schizophrenia from some autobiographical accounts. Schizophrenia Bulletin, 3(4), 562-567. https://dx.doi.org/10.1093/schbul/3.4.560

[5] Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346

[6] Obreshkova, D., Kandilarov, I., Angelova, V. T., Iliev, Y., Atanasov, P., & Fotev, P. S. (2017). PHARMACO-TOXICOLOGICAL ASPECTS AND ANALYSIS OF PHENYLALKYLAMINE AND INDOLYLALKYLAMINE HALLUCINOGENS. PHARMACIA, 64(1), 41-42. https://www.researchgate.net/profile/Violina_Angelova2/publication/317528151_Pharmaco-toxicological_aspects_and_analysis_of_phenylalkylamine_and_indolylallkylamine_hallucinogens_Review/links/593d59f50f7e9b3317a45adf/Pharmaco-toxicological-aspects-and-analysis-of-phenylalkylamine-and-indolylallkylamine-hallucinogens-Review.pdf

[7] Luke, D., & Terhune, D. B. (2013). The induction of synaesthesia with chemical agents: a systematic review. Frontiers in psychology, 4, 753. https://dx.doi.org/10.3389%2Ffpsyg.2013.00753

[8] Dillon, P., Copeland, J., & Jansen, K. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug & Alcohol Dependence, 69(1), 26. https://doi.org/10.1016/S0376-8716(02)00243-0

[25B_multiple-9] 9.0 ^9.1 Papoutsis, I., Nikolaou, P., Stefanidou, M., Spiliopoulou, C., & Athanaselis, S. (2015). 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicology, 33(1), 4. https://doi.org/10.1007/s11419-014-0242-9

[25C_multiple-10] 10.0 ^10.1 Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., ... & Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014. https://dx.doi.org/10.1155%2F2014%2F734749

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]